Condition: Acute Myeloid Leukemia, Adult · Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
Treatment of patients with newly diagnosed AML who are not eligible for intensive chemotherapy has remained an area of high unmet medical need. The combination therapy with two medicines, azacitidine and venetoclax, is the usual plan of action. This has brought significant progress in the treatment, but it nevertheless is not curative and the disease does relapse over time. Revumenib blocks a specific molecule called menin in the cell nucleus. Some types of AML are reliant on menin working properly. These are leukemia cells with a change in the DNA, i.e. a mutation in the NPM1 or KMT2A gene. Revumenib can prevent the production of these types of leukemia cells by disrupting the production of this menin. The current study investigates whether adding revumenib to the combination therapy improves the prognosis for AML patients with a mutation in the NPM1 or KMT2A gene. This is a randomized, double-blind, placebo-controlled clinical study where subjects will be treated until disease progression, or development of side effects or death. From the moment of inclusion of the last patient, there will be a 4-year observational follow-up study in order to register survival duration and follow-up visits. Approximately 415 previously untreated patients with a mutation in the NPM1 or KMT2A gene and with newly diagnosed AML, who are not eligible for intensive chemotherapy. Patients must be ≥18 years of age.
This description comes directly from the study's public registry record.
Gerwin Huls, MD · +31-(0)107041560 · HOVON@erasmusmc.nl
Paresh Vyas, MD · +44(0)7817248950 · paresh.vyas@imm.ox.ac.uk
Always discuss trial participation with your own doctor first.
| DE-Berlin-CAMPUSBENFRANKLIN | Berlin, Germany | Not Yet Recruiting |
| DE-Berlin-CAMPUSVIRCHOW | Berlin, Germany | Not Yet Recruiting |
| DE-Berlin-VIVANTESNEUKOLLN | Berlin, Germany | Not Yet Recruiting |
| DE-Bochum-RUB | Bochum, Germany | Not Yet Recruiting |
| DE-Bonn-UNIBONN | Bonn, Germany | Not Yet Recruiting |
| DE-Braunschweig-KLINIKUMBRAUNSCHWEIG | Braunschweig, Germany | Not Yet Recruiting |
| DE-Bremen-KBM | Bremen, Germany | Not Yet Recruiting |
| DE-Darmstadt-KLINIKUMDARMSTADT | Darmstadt, Germany | Not Yet Recruiting |
| DE-Essen-KEM | Essen, Germany | Not Yet Recruiting |
| DE-Flensburg-MALTESER | Flensburg, Germany | Not Yet Recruiting |
| DE-Frankfurt-KLINIKUMFRANKFURT | Frankfurt, Germany | Not Yet Recruiting |
| DE-Freiburg-UNIKLINIKFREIBURG | Freiburg im Breisgau, Germany | Not Yet Recruiting |
+ 55 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06652438